DAILY EXTRA – The Daily Extra released a report that the first clinical trial for an injection PrEP regimen has started. The idea is that with one injection the recipient would be protected for 2 months.
The purpose of injection is similar to using Truvada as PrEP, but instead of taking a pill daily, the anti-HIV drug, cabotegravir, is injected once every eight weeks with hopes that it will prevent the spread of HIV.
With the recent findings that Beta Blog reported with adherence issues to PrEP in young men that have sex with men (YMSM) this could be a huge advancement in cutting down the amount of new HIV infections, which are scarily on the rise.
A new report came out this week discussing the probable reduction in new HIV infections if more of the at risk population was on PrEP.